It is our constant endeavor to both develop and apply new technologies to bring about innovative capabilities to help nurture molecules from discovery to commercialization. A true example of this commitment is reflected in our ongoing efforts to invest in both capacity and innovation for our portfolio of advanced therapy end-to-end solutions, so that we can continue to offer speed, flexibility and scale to help address fundamental challenges faced by the industry. To this point, we are pleased to announce the opening of our new viral vector manufacturing facility in Plainville, Mass.
The new cGMP-compliant Plainville facility significantly expands our clinical and commercial viral vector capacity to six sites in the U.S and Europe and is part of a strategy to provide customers with fully integrated capabilities that connect the entire cell and gene therapy value chain — from early development and clinical scale-up to commercial manufacturing. The 300,000 square foot, state-of-the-art facility will support the development, testing and manufacture of viral vectors, add approximately 300 jobs to the Commonwealth, and is comprised of sustainable construction design, flexible laboratory and production suites, and adjacent warehousing and office space.